Literature DB >> 23602182

DRESS syndrome: Part I. Clinical perspectives.

Zain Husain1, Bobby Y Reddy, Robert A Schwartz.   

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, also referred to as drug-induced hypersensitivity syndrome, is a distinct, potentially life-threatening adverse reaction. It is seen in children and adults most often as a morbilliform cutaneous eruption with fever, lymphadenopathy, hematologic abnormalities, and multiorgan manifestations. Historically, it was most frequently linked with phenytoin and known as phenytoin hypersensitivity syndrome. However, because many other medications were found to produce the same reaction, another name was in order. Anticonvulsants and sulfonamides are the most common offending agents. Its etiology has been linked with lymphocyte activation, drug metabolic enzyme defects, eosinophilia, and human herpesvirus-6 reactivation. DRESS has a later onset and longer duration than other drug reactions, with a latent period of 2 to 6 weeks. It may have significant multisystem involvement, including hematologic, hepatic, renal, pulmonary, cardiac, neurologic, gastrointestinal, and endocrine abnormalities. This syndrome has a 10% mortality rate, most commonly from fulminant hepatitis with hepatic necrosis.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23602182     DOI: 10.1016/j.jaad.2013.01.033

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  77 in total

1.  Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome.

Authors:  J Ahluwalia; K Abuabara; M J Perman; A C Yan
Journal:  Br J Dermatol       Date:  2015-02-27       Impact factor: 9.302

2.  What is This Rash?

Authors:  Timothy P Gleeson; Matthew K Griswold; John Broach; Kavita M Babu
Journal:  J Med Toxicol       Date:  2016-06

Review 3.  HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Authors:  Khatiya Chelidze; Cristina Thomas; Aileen Yenting Chang; Esther Ellen Freeman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

4.  Acute mucocutaneous methotrexate toxicity with marked tissue eosinophilia.

Authors:  Luis J Borda; Andrew Ross; Gabriel Villada; Clara Milikowski
Journal:  BMJ Case Rep       Date:  2018-04-07

Review 5.  Drug reactions with eosinophilia and systemic symptoms.

Authors:  B Scrace; A Fityan; C Bigham
Journal:  BJA Educ       Date:  2020-01-08

6.  A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms.

Authors:  Francois X Rwandamuriye; Abha Chopra; Katherine C Konvinse; Linda Choo; Jason A Trubiano; Christian M Shaffer; Mark Watson; Simon A Mallal; Elizabeth J Phillips
Journal:  J Mol Diagn       Date:  2019-05-31       Impact factor: 5.568

7.  Lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) during primary Epstein-Barr virus (EBV) infection.

Authors:  Ibrahim Tawhari; Fawaz Tawhari; Mossab Aljuaid
Journal:  BMJ Case Rep       Date:  2018-01-23

8.  Drug Reaction, Eosinophilia and Systemic Symptoms (DRESS) syndrome secondary to allopurinol with early lymphadenopathy and symptom relapse.

Authors:  Rhiannon Turney; Jordan Peter Skittrall; Joseph Donovan; Daniel Agranoff
Journal:  BMJ Case Rep       Date:  2015-10-05

9.  DRESS syndrome presenting after initiation of mycobacterium avium complex osteomyelitis treatment.

Authors:  Paul W Blair; Douglas Herrin; Nawaf Abaalkhail; Wesley Fiser
Journal:  BMJ Case Rep       Date:  2015-10-05

Review 10.  The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review.

Authors:  Stephanie S Eng; Magee L DeFelice
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.